Recent News

• 05.05.2025 - Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
• 04.17.2025 - Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
• 04.14.2025 - Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
• 04.14.2025 - Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
• 04.14.2025 - Can-Fite Reports 2024 Financial Results and Clinical Update

Recent Filings

• 05.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.05.2025 - EX-99.1 EX-99.1
• 04.23.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.17.2025 - EFFECT Notice of Effectiveness
• 04.17.2025 - EX-99.1 EX-99.1
• 04.17.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.16.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.15.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 04.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]